1. Right drug, wrong dosage: insights from the PAVE-AF antithrombotic study in older patients with atrial fibrillation
- Author
-
George Giannakoulas, George Hahalis, Sotirios Kyrikos, Stylianos Tzeis, Paraskevi Savvari, Konstantinos Tsatiris, Kimon Stamatelopoulos, Ioannis Skiadas, Sotirios Patsilinakos, Spyridon Kourouklis, and Damianos Menegas
- Subjects
Male ,medicine.medical_specialty ,Administration, Oral ,Article ,Dabigatran ,Anticoagulation ,Antithrombotic ,Dosage ,Internal medicine ,Medicine ,Humans ,Dosing ,NOAC ,Prospective Studies ,Medical prescription ,Stroke ,Aged, 80 and over ,Rivaroxaban ,Dose-Response Relationship, Drug ,business.industry ,Age Factors ,Anticoagulants ,Atrial fibrillation ,Hematology ,medicine.disease ,Older ,Cross-Sectional Studies ,Apixaban ,Female ,Cardiology and Cardiovascular Medicine ,business ,Platelet Aggregation Inhibitors ,medicine.drug - Abstract
Optimal antithrombotic treatment of older patients is usually impeded by several prevailing misconceptions. The aim of our study was to assess the type, dosage and predictors of antithrombotic therapy in older patients with non-valvular atrial fibrillation (NVAF). PAVE-AF was a prospective, cross-sectional study, including NVAF patients ≥ 80 years from 30 participating centers. Demographic data, comorbidities and treatment patterns were documented in a single visit. Patients treated with non-vitamin K oral anticoagulants (NOACs) were further classified into three dosing categories (recommended, underdosing and overdosing). Among 1018 patients (85.4±4.0 years), 88.4% received anticoagulants (AC), 8% antiplatelets (AP) and 3.6% no treatment. The primary reason for AP administration was physician concern of bleeding followed by patient denial. Patients ≥90 years had two times greater probability to receive AP therapy compared to patients
- Published
- 2020